Drug Profile

Verekitug - Upstream Biosciences

Alternative Names: ASP-7266; UPB-101

Latest Information Update: 03 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astellas Pharma
Developer Upstream Biosciences
Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
Mechanism of Action CRLF2 protein antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Asthma; Chronic obstructive pulmonary disease; Nasal polyps

Most Recent Events

01 Sep 2026 Upstream Bio plans to launch Verekitug in Asthma and Rhinosinusitis in 2030
01 Sep 2026 Upstream Bio plans to submit a Biologics License Application (BLA) to the US FDA in Asthma and Rhinosinusitis in 2030
11 Aug 2026 End-of-Phase II interactions with the US FDA for both severe asthma and nasal polyps (CRSwNP) are on track

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com